Response to teprotumumab in thyroid eye disease patients of long duration and high clinical activity score
作者
Darren A. Chen,Annika G. Samuelson,Sierra K. Ha,Tatiana R. Rosenblatt,Amee Deepak Azad,Sri Meghana Konda,Lisa Y. Lin,Natalie Wolkow,Nahyoung G. Lee,Michael K. Yoon,Suzanne K. Freitag
Purpose To evaluate the efficacy of teprotumumab in a subset of thyroid eye disease (TED) patients with prolonged disease duration and high clinical activity score (CAS).Methods This is a retrospective study of all TED patients who underwent eight infusions of teprotumumab and had a consistently documented CAS ≥ 4 for at least 2 years prior to teprotumumab initiation at a single institution. Primary outcome measures included proptosis response (difference in median pre- and post-treatment Hertel exophthalmometry), CAS response (difference in median pre- and post‑treatment CAS), and diplopia response (≥1 point improvement in Gorman diplopia score), comparing pre-treatment values to post-treatment measurements at the immediate follow-up visit using Mann-Whitney U testing. Results Of 198 patients who initiated teprotumumab treatment from April 1 2020 to March 31 2024, 8 patients met inclusion criteria. The median TED duration, measured from the first clinic visit to the clinic visit closest to initiation of teprotumumab was 42.3 months; the average follow‑up interval was 32.7 months. The median pre-treatment Hertel measurement was 24.25 mm (IQR 4.88) compared to a post-treatment measurement of 21.81 mm (IQR 4.63) (p < 0.001) - a mean proptosis reduction of 2.44 mm (13.6%). The median pre-treatment CAS was 5 (IQR 1) compared to a post-treatment CAS of 1 (IQR 2.25) (p < 0.001). The median pre-treatment diplopia score was 1.5 (IQR 1.25) compared to a post-treatment score of 0.5 (IQR 1.0) (p = 0.04).Conclusions This retrospective study suggests that teprotumumab can be an effective treatment for patients with thyroid eye disease who have prolonged disease duration and high clinical activity.